| Nov 15 |
Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now
|
| Nov 13 |
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem
|
| Nov 12 |
Sarepta recent weakness brings buying opportunity, says JPMorgan
|
| Nov 9 |
Notable analyst calls this week: Carvana, Devon Energy and Palantir among top picks
|
| Nov 8 |
Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step
|
| Nov 8 |
Sarepta price target lowered to $193 from $200 at Baird
|
| Nov 7 |
Sarepta upgraded at Cantor on pipeline, growth potential
|
| Nov 7 |
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
|
| Nov 7 |
Sarepta scraps a Duchenne drug as gene therapy sales rise
|
| Nov 7 |
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
|
